The state of Florida currently has 54 active clinical trials seeking participants for Alzheimer's Disease research studies. These trials are conducted in various cities, including Miami, Tampa, Jacksonville and Orlando.
Dominantly Inherited Alzheimer Network (DIAN)
NCT00869817
Recruiting
The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Mayo Clinic Jacksonville, Jacksonville, Florida
Conditions: Alzheimer's Disease
Register for Updates
The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's
NCT03649724
Recruiting
The LUCINDA Trial is a three-site, phase II, randomized, double-blind, placebo-controlled study of leuprolide acetate (Eligard) in women with Mild Cognitive Impairment or Alzheimer's Disease taking a stable dose of a cholinesterase inhibitor medication like donepezil. Its objective is to assess the efficacy of a 48-week regimen of leuprolide (22.5 mg per 12 weeks) compared to placebo on cognitive function, global function and plasma and neuroimaging biomarkers.
Gender:
Female
Ages:
Between 60 years and 120 years
Trial Updated:
04/22/2024
Locations: University of Miami Miller School of Medicine, Boca Raton, Florida
Conditions: Alzheimer Disease, Mild Cognitive Impairment
Register for Updates
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (Hope Study, CA-0011)
NCT05637801
Recruiting
This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer's disease. Approximately 530 subjects will be randomized to 12 months of daily treatment with either Active or Sham Sensory Stimulation Systems. Efficacy will be measured using the Alzheimer's Disease Cooperative Study- Activities of Daily Living (ADCS-ADL) assessment and a combined statistical test (CST) of the ADCS-ADL and the Mini-Mental State E... Read More
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
04/22/2024
Locations: JEM Research Institute, Atlantis, Florida +22 locations
Conditions: Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease 9, Alzheimer Disease 4, Alzheimer Disease 7, Alzheimer Disease 17, Alzheimer's Dementia Late Onset, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 8, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 18, Alzheimer Disease 19, Dementia, Dementia Alzheimers, Dementia, Mild, Dementia of Alzheimer Type, Dementia Moderate, Dementia Senile, Mild Cognitive Impairment, Mild Dementia, MCI, Cognitive Impairment, Cognitive Decline, Cognitive Impairment, Mild
Register for Updates
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
NCT04639050
Recruiting
The purpose of this study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of multiple-ascending intravenous (IV) doses of RO7126209 in participants with prodromal or mild to moderate Alzheimer's disease (AD), who are amyloid positive based on amyloid positron emission tomography (PET) scan.
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
04/18/2024
Locations: JEM Research LLC, Atlantis, Florida +12 locations
Conditions: Alzheimers Disease
Register for Updates
A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease
NCT05744401
Recruiting
A long-term extension study to evaluate the safety, tolerability, and efficacy of AL002 in participants with Early Alzheimer's Disease.
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
04/15/2024
Locations: Charter Research, Lady Lake, Florida
Conditions: Alzheimer's Disease
Register for Updates
Neurologic Stem Cell Treatment Study
NCT02795052
Recruiting
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http://mdstemcells.com/nest/
Gender:
All
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: MD Stem Cells, Coral Springs, Florida
Conditions: Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders, Stroke, Traumatic Brain Injury, Cadasil, Chronic Traumatic Encephalopathy, Cerebral Infarction, Cerebral Ischemia, Cerebral Stroke, Cerebral Hemorrhage, Parkinson, Multi-System Degeneration, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, ALS, Amyotrophic Lateral Sclerosis, Neuropathy, Diabetic Neuropathies, Alzheimer Disease, Dementia, Frontotemporal Dementia, Lewy Body Disease, Cognitive Impairment, Lewy Body Variant of Alzheimer Disease
Register for Updates
A Scalable Nutrition Adherence Intervention
NCT06121986
Recruiting
Objective 1: To scale-up the nutrition adherence intervention for testing in predominantly Black and African-American rural communities in North Florida. The investigators hypothesize that: 1. The protocol will produce at least 75% of participants obtaining measurable levels of urine ketones (e.g., good adherence) in the Mediterranean-Ketogenic nutrition (MKN) group and an average score of >9 on the MEDAS questionnaire in the Mediterranean group during the 10-week program. Objective 2: To eva... Read More
Gender:
All
Ages:
Between 55 years and 85 years
Trial Updated:
04/03/2024
Locations: 2010 Levy Ave - Center for Translational Behavioral Science, Tallahassee, Florida
Conditions: Alzheimer Disease, Mild Cognitive Impairment
Register for Updates
48-hour Ambulatory EEG Monitoring in Early Onset Alzheimer's Disease
NCT04002583
Recruiting
Researchers are trying to determine the frequency of seizures and epilepsy in patients with Early-onset Alzheimer's disease (EOAD) using a 48-hour computer assisted ambulatory electroencephalogram.
Gender:
All
Ages:
Between 40 years and 64 years
Trial Updated:
03/21/2024
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Early Onset Alzheimer Disease
Register for Updates
A Diagnostic Test for Dementia With Lewy Bodies
NCT05479552
Recruiting
The Syn-D Study will be evaluating α-synuclein in patients with suspected MCI-AD and MCI-DLB. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between neurodegenerative diseases.
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
03/06/2024
Locations: University of Miami, Boca Raton, Florida +1 locations
Conditions: MCI-AD, Early Stage Alzheimer's Disease, MCI-DLB, Early Stage Dementia With Lewy Bodies
Register for Updates
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease
NCT03671889
Recruiting
The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
03/04/2024
Locations: Delray Medical Center & Florida Atlantic University, Delray Beach, Florida +4 locations
Conditions: Alzheimer Disease
Register for Updates
Combating Alzheimer's Through Sleep and Exercise
NCT04855630
Recruiting
The purpose of this research is to see how sleep and exercise affects dementia risk over time.
Gender:
All
Ages:
Between 45 years and 80 years
Trial Updated:
02/29/2024
Locations: University of Miami Hospitals, Miami, Florida
Conditions: Alzheimer Disease, Dementia
Register for Updates
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
NCT06079190
Recruiting
The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment [MCI] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
02/12/2024
Locations: GSK Investigational Site, DeLand, Florida +5 locations
Conditions: Alzheimer's Disease
Register for Updates